Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) shot up 6.2% during mid-day trading on Thursday after Scotiabank raised their price target on the stock from $36.00 to $37.00. Scotiabank currently has a sector outperform rating on the stock. Liquidia traded as high as $14.93 and last traded at $15.06. 963,834 shares changed hands during trading, a decline of 11% from the average session volume of 1,078,928 shares. The stock had previously closed at $14.18.
A number of other research analysts have also weighed in on LQDA. Raymond James upped their price objective on Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Needham & Company LLC reaffirmed a "buy" rating and issued a $25.00 target price on shares of Liquidia in a research report on Wednesday. Wall Street Zen raised shares of Liquidia from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer set a $13.00 price target on Liquidia and gave the company an "underperform" rating in a report on Monday, May 19th. Finally, HC Wainwright increased their target price on shares of Liquidia from $29.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $26.67.
Check Out Our Latest Research Report on LQDA
Insider Transactions at Liquidia
In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the sale, the chief executive officer now directly owns 1,006,420 shares in the company, valued at $13,657,119.40. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jason Adair sold 1,856 shares of Liquidia stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the transaction, the insider now directly owns 184,304 shares of the company's stock, valued at $2,501,005.28. The trade was a 1.00% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,138 shares of company stock valued at $450,233. Company insiders own 26.50% of the company's stock.
Institutional Trading of Liquidia
Institutional investors and hedge funds have recently made changes to their positions in the stock. Hurley Capital LLC purchased a new position in shares of Liquidia in the first quarter worth $32,000. GAMMA Investing LLC raised its position in shares of Liquidia by 65.6% in the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after purchasing an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Liquidia in the fourth quarter worth about $59,000. Summit Investment Advisors Inc. lifted its position in Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after acquiring an additional 1,719 shares in the last quarter. Finally, Quarry LP purchased a new position in Liquidia in the 1st quarter worth about $79,000. Hedge funds and other institutional investors own 64.54% of the company's stock.
Liquidia Price Performance
The stock's 50-day moving average is $14.71 and its two-hundred day moving average is $13.72. The company has a market cap of $1.28 billion, a P/E ratio of -9.22 and a beta of 0.24.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The business had revenue of $3.12 million for the quarter, compared to analysts' expectations of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, analysts predict that Liquidia Co. will post -1.51 EPS for the current year.
Liquidia Company Profile
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read More
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
